Responses
Poster
IGCS20_1382
357 GLS-010 (Zimberelimab), a novel fully human anti-PD-1 mAb in chinese patients with recurrent/metastatic cervical cancer: results from a multicenter, open-label, single-arm phase II trial
Compose a Response to This Article
Other responses
No responses have been published for this article.